Bildkälla: Stockfoto

Kancera: Underestimated optionality - Redeye

Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting myocardial infarction and ovarian cancer. As clinical studies indicate a widely applicable treatment mechanism, we believe the stock market currently underestimates the upside optionality in the case.

Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting myocardial infarction and ovarian cancer. As clinical studies indicate a widely applicable treatment mechanism, we believe the stock market currently underestimates the upside optionality in the case.
Börsvärldens nyhetsbrev
ANNONSER